Why PBM reform remains critical for Florida patients

As Florida’s leaders continue to confront affordability challenges facing families and seniors, prescription drug costs remain one of the most persistent financial pressures in household budgets.

While medical innovation has produced remarkable new treatments, the system that determines what patients actually pay for those treatments remains deeply opaque.

At the center of that system are Pharmacy Benefit Managers (PBMs), who were originally designed to negotiate discounts from drug manufacturers on behalf of insurers and employers.

In theory, they would use their purchasing power to secure rebates and pass savings along to patients. In practice, the system has evolved into one dominated by a small number of vertically integrated corporations that control drug formularies, reimbursement rates, and pharmacy networks.

Today, three PBM corporations control more than 80% of the national market. Many are vertically integrated with major insurers and affiliated pharmacies. This structure allows them to influence not only which medications are covered, but also where patients fill prescriptions and how much independent pharmacies are reimbursed.

The result is a system that often lacks transparency, reduces competition, and leaves patients unsure whether negotiated “savings” are ever reaching them.

For seniors living on fixed incomes, even small increases in out-of-pocket prescription costs can create difficult tradeoffs. High deductibles and coinsurance structures mean patients frequently pay based on a drug’s list price, not the discounted price negotiated later in the supply chain.

At the same time, independent pharmacies across Florida, particularly in rural and underserved communities, report increasing financial strain under reimbursement models and network participation requirements established by PBMs.

When local pharmacies close, patients lose convenient access to trusted health care providers, and communities lose small businesses that have long served as neighborhood anchors.

These pressures are not theoretical. They are felt every day by patients at the pharmacy counter.

Recognizing these concerns, Florida lawmakers took action in 2023 when the Legislature passed the Prescription Drug Reform Act with bipartisan support. The law sought to increase transparency and accountability in PBM operations, limit certain steering practices, and empower patients with clearer pricing information.

Among the reforms highlighted in that legislation were measures designed to curb anti-consumer practices, reduce conflicts of interest arising from vertical integration, and provide greater visibility into prescription drug price increases.

The legislation represented a significant acknowledgment that PBMs play a powerful and largely unseen role in shaping drug costs.

Florida’s 2023 reforms were an important first step. But affordability challenges persist, and the national conversation around PBM reform continues to evolve.

Today, one of the central concerns remains the rebate-driven model itself. Under this structure, PBMs negotiate rebates tied to a drug’s list price. Critics argue this dynamic can incentivize higher list prices, since larger rebates can generate greater retained revenue within the system.

Recent federal discussions have focused on dismantling this “back-end rebate” structure in favor of requiring transparent, point-of-sale discounts and flat service fees. The goal is to ensure negotiated savings are reflected directly in patients’ copays, deductibles, and premiums rather than retained within complex rebate arrangements.

For Florida policymakers, the question is how to build on prior reforms to ensure the state’s drug pricing framework prioritizes transparent pricing practices, true competition among PBMs and insurers, protection against pharmacy steering and anti-competitive behavior, and assurance that negotiated savings reach patients at the pharmacy counter.

Reform is not about limiting innovation or restricting access to new treatments. Florida remains a state that supports medical advancement and patient choice. Rather, the focus is on making sure the system that bridges manufacturers and patients operates fairly and competitively.

The broader debate over drug pricing often becomes polarized between manufacturers, insurers, and regulators. But from a patient’s perspective, the issue is simpler: affordability and access.

Florida policymakers can continue strengthening transparency requirements, scrutinizing vertically integrated structures, and examining whether rebate-driven incentives align with patient interests. Ensuring that negotiated discounts are visible and directly applied at the point of sale could provide meaningful relief for seniors and working families.

Florida has already demonstrated that bipartisan action on drug pricing reform is possible. As affordability remains a top concern across the state, continued attention to PBM reform represents a practical, targeted approach to delivering savings without sacrificing innovation or access.

In a health care system that too often obscures how prices are set, transparency and competition remain the most reliable tools for protecting patients. PBM reform is the most critical piece of ensuring Florida families pay fair prices for the medications they depend on every day.